Phil Kerpen

In 2003, I opposed the Medicare prescription drug bill, in large part because I expected that - like all other government entitlement programs - it would end up costing far more than initially projected. I was wrong.

The program's structure, based on competing private plans, made Part D unlike all entitlements that had come before. Indeed, it is a model for reforming the rest of Medicare. The plans compete intensely to sign up seniors. The incentives are aligned to avoid administrative waste and keep costs down, including negotiating for the best prices on drugs. An amazing 90 percent of seniors are satisfied with their coverage according to a recent survey.

Estimates from the Congressional Budget Office (CBO) show that since the program started in 2006, it is on track to spend 45 percent less than the original estimate over its first ten years. And the premiums paid by seniors are also much lower, about $30 per month for the past three years, which is less than half the original projection.

This astonishing success stands in stark contrast to the daily disaster story that is the Patient Protection and Affordable Care Act (PPACA) exchanges. Those heavily regulated marketplaces offer limited choices and sharply higher costs than what most people are used to paying.

In a logical world, the Centers for Medicare and Medicaid Services (CMS) would be looking for ways to make the PPACA exchanges look more like Part D. Unfortunately, they are doing precisely the opposite. On January 10, 2014, CMS proposed a rule making major changes in the market structure of Part D that will significantly reduce choice and competition.

Most outrageously, the rule creates an arbitrary new restriction on plan contracts and bids. The rule would set a limit of exactly two bids a plan may offer in a region, one basic and one extended. Seniors would lose many of the choices they presently enjoy, and competition and innovation would be curtailed.

The rule also undermines the non-interference provision that prevents de facto imposition of price controls. This provision was a major point of contention in the original legislation because large-scale government drug purchasing risks imposition of price controls that would undercut the incentives for developing new miracle cures. (It costs over $1.2 billion on average to bring a new drug to market.)

Phil Kerpen

Phil Kerpen is president of American Commitment, a columnist on Fox News Opinion, chairman of the Internet Freedom Coalition, and author of the 2011 book Democracy Denied.

American Commitment is dedicated to restoring and protecting America’s core commitment to free markets, economic growth, Constitutionally-limited government, property rights, and individual freedom.

Washingtonian magazine named Mr. Kerpen to their "Guest List" in 2008 and The Hill newspaper named Mr. Kerpen a "Top Grassroots Lobbyist" in 2011.

Mr. Kerpen's op-eds have run in newspapers across the country and he is a frequent radio and television commentator on economic growth issues.

Prior to joining American Commitment, Mr. Kerpen served as vice president for policy at Americans for Prosperity. Mr. Kerpen has also previously worked as an analyst and researcher for the Free Enterprise Fund, the Club for Growth, and the Cato Institute.

A native of Brooklyn, N.Y., Mr. Kerpen currently resides in Washington, D.C. with his wife Joanna and their daughter Lilly.